Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.48 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806686 | 0.86 | EP300 (0.42) | EP300KAT2BKAT8KEAP1HSD17B1 | |
| SCHEMBL6806548 | 0.80 | ALDH1A1 (0.43) | EP300KAT2BKAT8KEAP1NFE2L2 | |
| SCHEMBL3378181 | 0.77 | CA1 (0.43) | ALDH1A1SMN1; SMN2CA1CA2CA9 | |
| SCHEMBL6111717 | 0.76 | EP300 (0.61) | EP300KAT2BKAT8KEAP1HSD17B2 | |
| SCHEMBL5965425 | 0.75 | KEAP1 (0.67) | EP300KAT2BKAT8KEAP1NFE2L2 | |
| SCHEMBL829952 | 0.75 | G6PD (0.71) | EP300KAT2BKAT8KEAP1HSD17B1 | |
| SCHEMBL3382919 | 0.75 | NAAA (0.49) | ALDH1A1SMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL10391939 | 0.74 | KEAP1 (0.61) | KEAP1NFE2L2ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL8605375 | 0.74 | KEAP1 (0.50) | EP300KAT2BKAT8KEAP1HSD17B1 | |
| SCHEMBL11234851 | 0.74 | EP300 (0.39) | EP300KAT2BKAT8KEAP1HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436914-B1 | TREATING DIABETES, OBESITY, DEPRESSION, ACHALASIA OR INTESTINAL HYPERMOTILITY DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-20 | — | — | US | disclosed |
| US-20020026065-A1 | 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as beta 3 adrenergic agonists | SHER PHILIP M (US) | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026065-A1 | 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as beta 3 adrenergic agonists | ADRB3, ADRB1, ADRA1A | EP300 1756/4885KAT2B 1390/4885KAT8 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.